Revenue ($USD) : $2,974,489,000
R&D spend : $154,351,000
Employees : 14,500
Fiscal year end : 12/31/2023
CEO : Liam Kelly

www.teleflex.com

Teleflex specializes in critical care and surgical technologies. Its portfolio spans vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Highlights in 2024 included the launch of the UroLift 2 for treating benign prostatic hyperplasia (BPH) symptoms as an alternative to medications and major surgery. The company also initiated a serious balloon catheter recall related to reports of three deaths. –SW